lutetium has been researched along with vasoactive intestinal peptide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, N; Choi, J; Coppola, D; Gardner, NM; Kvols, LK; Kwekkeboom, DJ; Malafa, MP; Nasir, A; Strosberg, J; Teunissen, JJ | 1 |
| Blažević, A; Brabander, T; de Herder, WW; Feelders, RA; Hofland, J; Kam, BLR; Teunissen, JJM; Zandee, WT | 1 |
2 other study(ies) available for lutetium and vasoactive intestinal peptide
| Article | Year |
|---|---|
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels.
Topics: Calcitonin; Combined Modality Therapy; Diarrhea; Female; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Middle Aged; Pancreatic Neoplasms; Paraneoplastic Endocrine Syndromes; Peptides, Cyclic; Radiopharmaceuticals; Vasoactive Intestinal Peptide | 2008 |
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Coordination Complexes; Female; Gastrins; Glucagon; Humans; Insulin; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreas; Pancreatic Neoplasms; Quality of Life; Radiation Dosage; Radioisotopes; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Vasoactive Intestinal Peptide | 2019 |